SIETES :: 93213 citas

Resultados de la búsqueda por TICLOPIDINA REFINAR BÚSQUEDA

1.

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]

2.

Varga S, Alcusky M, Keith SW, Hegarty SE, Del Canale S, Lombardi M, Maio V. Hospitalization rates during potentially inappropriate medication use in a large population-based cohort of older adults. Br J Clin Pharmacol 2017;83:2572-80. [Ref.ID 102117]

3.

Anónimo. Diarrhées d'origine médicamenteuse. Prescrire 2016;36:748-55. [Ref.ID 100894]

4.

Anónimo. Antithrombotic drugs. Med Lett Drugs Ther 2014;56:103-8. [Ref.ID 98343]

5.

Brilakis ES, Patel VG, Banerjee S. Medical management after coronary stent implantation: a review.. JAMA 2013;310:189-98. [Ref.ID 96243]

6.

Anekwe L. St John's wort causes most drug interactions, finds review of 85 studies. BMJ 2012;345:5. [Ref.ID 94215]

7.

Anónimo. Transport d'anions ou de cations organiques et interactions. Prescrire 2012;32:676-7. [Ref.ID 93662]

8.

Anónimo. Pamplemousses: des interactions avec les médicaments. Prescrire 2012;32:674-9. [Ref.ID 93661]

9.

Anónimo. Ticagrélor. Syndromes coronariens aigus: pas d'emballement. Prescrire 2011;31:488-93. [Ref.ID 90880]

10.

Anónimo. Clopidogrel interaction. JAMA 2010;303:322. [Ref.ID 87726]

11.

Anónimo. Information for Healthcare Professionals: Update to the labeling of Clopidogrel Bisulfate (marketed as Plavix) to alert healthcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). FDA 2009:17 noviembre. [Ref.ID 87066]

12.

Naughton C. Drug-induced nephrotoxcicity. American Family Physician 2008;78:743-50. [Ref.ID 87065]

13.

García del Pozo J, de Abajo FJ. Utilización de antiagregantes y anticoagulantes en España, 1992-2006. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2009:. [Ref.ID 86452]

14.

Anónimo. Prévention par antiagrégants chez les patients à risque cardiovasculaire très élevé. Prescrire 2009;29:283. [Ref.ID 85593]

15.

Lip GYH. Managing the anticoagulated patient with atrial fibrillation at high risk of stroke who needs coronary intervention. BMJ 2008;337:1110-2. [Ref.ID 84512]

16.

Ibáñez L, Vidal X, Laporte JR. Agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med 2008;148:319-20. [Ref.ID 82254]

17.

Charlish P. Product problems plague industry. Scrip 100 2007:S54-7. [Ref.ID 82028]

18.

Mohler III ER. Atherothrombosis - wave goodbye to combined anticoagulation and antiplatelet therapy?. N Engl J Med 2007;357:293-6. [Ref.ID 80590]

19.

The Warfarin Antiplatelet Vascular Evaluation Trial Investigators. Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. N Engl J Med 2007;357:217-27. [Ref.ID 80584]

20.

Sabaté M, Ibáñez L, Pérez E, Vidal X, Buti M, Xiol X, Mas A, Guarner C, Forné M, Solà R, Castellote J, Rigau J, Laporte JR. Risk of acute liver injury associated with the use of drugs: a multicentre population survey. Aliment Pharmacol Ther 2007;25:1401-9. [Ref.ID 80401]